Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition | Oncology | JAMA Network Open | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Baghdadi  R. Biosimilars. Health Affairs Brief. Published July 21, 2017. Accessed November 4, 2019.
Hernandez  I, Good  CB, Shrank  WH, Gellad  WF.  Trends in Medicaid prices, market share, and spending on long-acting insulins, 2006-2018.  JAMA. 2019;321(16):1627-1629. doi:10.1001/jama.2019.2990PubMedGoogle ScholarCrossref
Peterson  J, Budlong  H, Affeldt  T, Skiermont  K, Kyllo  G, Heaton  A.  Biosimilar products in the modern U.S. health care and regulatory landscape.  J Manag Care Spec Pharm. 2017;23(12):1255-1259. doi:10.18553/jmcp.2017.23.12.1255PubMedGoogle Scholar
US Prescription Brand Net Pricing Data and Analysis. SSR Health website. Published 2019. Accessed November 4, 2019.
Medicaid Drug Rebate Program. website. Updated November 13, 2018. Accessed March 5, 2019.
Brill  A, Ippolito  B. Biologics are not natural monopolies. Health Affairs Blog. Published July 2, 2019. Accessed November 4, 2019.
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Research Letter
    Health Policy
    December 13, 2019

    Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition

    Author Affiliations
    • 1Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania
    • 2Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
    • 3Center for High-Value Health Care, Insurance Services Division, UPMC Health Plan, Pittsburgh, Pennsylvania
    JAMA Netw Open. 2019;2(12):e1917379. doi:10.1001/jamanetworkopen.2019.17379

    Biosimilars hold promise for reducing spending on biologics.1 Biosimilar prices are estimated to be 15% to 16% lower than originator products,2 but it is unclear how list prices, net prices, and discounts for the originator products change with biosimilar competition.

    We selected filgrastim, pegfilgrastim, infliximab, and insulin glargine as case studies because these were the only originator biologics that, by December 2018, faced competition from biosimilars (filgrastim-sndz, filgrastim-aafi, pegfilgrastim-jmdb, infliximab-dyyb, and infliximab-abda) or from other within-molecule substitutes (tbo-filgrastim and insulin glargine [Basaglar; Lilly]).3

    We obtained pricing data from January 2007 to June 2018 from SSR Health,4 which provides quarterly estimates of list prices, net prices, Medicaid discounts, and discounts in other payers for branded products with US sales reported by publicly traded companies. Quarterly net prices are calculated as the ratio between sales and number of units sold. Discounts are calculated as the ratio between the difference in list and net prices (numerator) and the list prices (denominator). Net prices and discounts capture all manufacturer concessions and not solely rebates.4 For each drug and year, we calculated the mean list and net prices and the mean discounts in Medicaid and other payers.5